Install
Research & Evidence
Trial design, systematic reviews, medical statistics, and guideline updates.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Research & Evidence
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
2+ hour, 24+ min ago (220+ words) Bezisterim showed a consistent advantage over placebo on 21 out of 22 individual endpoints in the overall study population An estimated 17–20 million U.S. adults live with Long COVID and currently have no FDA‑approved treatment options Conference call scheduled for 8:30 a.m....
Summit Therapeutics presents updated HARMONi OS data showing consistent survival benefit with ivonescimab; BLA PDUFA Nov 14, 2026
1+ hour, 1+ min ago (155+ words) tradingview.com Summit Therapeutics presents updated HARMONi OS data showing consistent survival benefit with ivonescimab; BLA PDUFA Nov 14, 2026 Summit Therapeutics announced updated HARMONi Phase III overall survival results showing a consistent OS benefit for ivonescimab plus chemotherapy versus placebo plus…...
Public consultation on including underrepresented populations in clinical trials
4+ hour, 16+ min ago (118+ words) The World Health Organization (WHO) invites stakeholders to contribute to a public consultation on improving the inclusion of underrepresented populations in clinical trials. The consultation will be open from 14 September 2026 to 29 October 2026. Responses will be analysed in aggregate. Individual respondents…...
Specialist NHS long Covid care linked to improved fatigue in major trial - The Pharmacist
2+ hour, 49+ min ago (411+ words) Around six in ten patients reported a clinically meaningful improvement in fatigue after 12 weeks of care at specialist NHS long Covid clinics, researchers found. The Stimulate-ICP trial involved more than 1,100 people receiving care through six NHS long Covid clinics in…...
BIVI: Bezisterim showed no overall statistical benefit in Long COVID, but subgroup signals warrant further study
3+ hour, 14+ min ago (75+ words) TradingView BIVI: Bezisterim showed no overall statistical benefit in Long COVID, but subgroup signals warrant further study The Phase 2 ADDRESS-LC trial of bezisterim in Long COVID did not achieve statistical significance in the overall population, though some pre-specified subgroups showed…...
UN: Highly persistent toxic waste threatens ‘many, if not all, human rights’ | 1news.az | News
3+ hour, 42+ min ago (484+ words) Poor management of toxic chemicals and hazardous waste threatens “many, if not all, human rights,” the newly appointed independent human rights independent expert on the rising threat told the Human Rights Council on Monday. According to UN, Bethanie Carney Almroth…...
J&J reports phase 2b data on less-frequent lung cancer treatment (JNJ:NYSE)
5+ hour, 33+ min ago (23+ words) J&J’s COPERNICUS Phase 2b results suggest less-frequent RYBREVANT FASPRO+LAZCLUZE dosing may improve EGFR NSCLC care with low side effects—read more....
FDA Grants Breakthrough Status to a Phage Treatment for Drug Resistant Staph Bloodstream Infections Ahead of Phase 3
14+ hour, 39+ min ago (1002+ words) The September 30 funding deadline that health agencies had been preparing for all summer is no longer the deadline. A stopgap bill signed into law on September 2 pushed the government's funding date to December 11, 2026, and with it the immediate risk of…...
‘The best day of our lives’: Brave Destiny, 7, marks end of her chemotherapy treatment after ‘superhero’ brother turned donor
21+ hour, 48+ min ago (485+ words) The Elston family celebrated ‘the best day of their lives’ when brave Destiny rang the bell to mark the end of her chemotherapy treatment last week. The seven-year-old Pinchbeck youngster hit the headlines last year when ‘superhero’ brother Luke defied…...
BioNTech Drug Doubles Survival vs Chemotherapy
16+ hour, 9+ min ago (1186+ words) Briefs Finance BioNTech Says Gotistobart Nearly Doubles Survival Versus Chemotherapy - In updated late-stage data, patients on gotistobart lived a median 18.5 months versus 10 months for those on standard chemotherapy. - Earlier readouts showed a 54% reduction in risk of death versus chemo, at…...